Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: A sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients

Table 2 Metabolic risk factors in patients treated with Irbesartan with or without the metabolic syndrome

		Patients without the metabolic syndrome¹							Patients with the metabolic syndrome¹
Components of the Met. Syn.		Baseline		3 months		9 months		Reduction †	Baseline		3 months		9 months		Reduction †
Blood pressure		mean	± SD	mean	± SD	mean	± SD		mean	± SD	mean	± SD	mean	± SD
systolic	mmHg	159.4	± 13.3	136.8*	± 11.3	131.9*	± 10.0	-27.5	160.7	± 13.4	139.1*	± 11.5	133.9*	± 10.5	-26.8
diastolic	mmHg	93.7	± 8.5	82.6*	± 7.5	79.9*	± 6.7	-13.8	94.3	± 8.8	83.8*	± 7.6	80.8*	± 6.8	-13.5
Fasting plasma
glucose	mg/dL	91.5	± 13.6	91.8	± 13.5	92.6**	± 15.0	1.1	120.9	± 30.1	114.2*	± 26.3	111.9*	± 25.0	-9.0
Abdominal obesity
men	cm	96.6	± 10.2	96.1*	± 10.2	95.9*	± 10.1	-0.7	111.3	± 12.8	109.9*	± 12.4	108.6*	± 12.6	-2.7
women	cm	85.9	± 11.9	85.5*	± 11.7	85.8**	± 11.8	-0.1	100.7	± 14.6	100*	± 14.6	99.2*	± 14.3	-1.5
Triglycerides	mg/dL	153.3	± 42.2	151.9*	± 40.2	151.7*	± 41.1	-1.6	217.5	± 62.5	196.6*	± 56.2	186.7*	± 53.2	-30.8
HDL cholesterol
men	mg/dL	48.6	± 6.2	49.2*	± 6.1	49.4*	± 6.2	0.8	41.8	± 7.6	44.2*	± 7.1	45.6*	± 7.0	3.8
women	mg/dL	52.2	± 5.6	52.2	± 5.8	51.9	± 5.8	-0.3	44.4	± 7.4	46.6*	± 6.9	47.7*	± 6.7	3.3

¹ doctors' diagnosis; statistical test applied: t-test; * p < 0.0001; ** p < 0.05; † reduction versus baseline

ISSN: 1475-2840